Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and

You are here:  Home >>  News >>  Top Stories >>  Bayer plea for stay on compulsory license dismissed

Bayer plea for stay on compulsory license dismissed

October 12, 2018 By biospectrumasia
Tag: Bayer , pharma , Nexavar

The Intellectual Property Rights Board dismissed Bayer's plea

Bangalore: The Intellectual Property Appellate Board in Chennai, India, has rejected pharma major Bayer's petition seeking a stay on compulsory license to Hyderabad-based Natco Pharma for sorafenib (Bayer's Nexavar). The by the Controller of Patents in India earlier this year for the drug which is used to treat liver and kidney cancer.

Bayer received a patent for Nexavar in India in 2008. In an appeal against the compulsory license, Bayer pointed out that Cipla had slashed the drug's price in India, rendering the compulsory licence unnecessary.

The board dismissed the petition for stay on the grounds that it would jeopardize the interests of the public who need the drug. The board also dismissed the charge against Natco Pharma by Bayer that the former was exporting the drug to Pakistan and China as well.


Editor's Note:

To apply for becoming a contributor of,

welcome to send your CV and sample works to us,


Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
live chat